Erasca touts early colorectal cancer data, trims a slate of trials and preclinical programs to refine focus

Amber Tong

Erasca believes it’s secured the early clinical data to show one of its targeted therapies holds promise as a “backbone” for drug combinations, particularly for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Erasca touts early colorectal cancer data, trims a slate of trials and preclinical programs to refine focus

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Eras­ca touts ear­ly col­orec­tal can­cer da­ta, trims a slate of tri­als and pre­clin­i­cal pro­grams to re­fine fo­cus

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Erasca touts early colorectal cancer data, trims a slate of trials and preclinical programs to refine focus